Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06542042

Application of Nanopore Adaptive Sequencing

Application of Oxford Nanopore Adaptive Sequencing Method in Infection Post Liver Transplantation

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Shenzhen Third People's Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Infection post liver transplantation is an important factor in the death in patients. The traditional method of diagnosing infection post liver transplantation is laboratory tests. But the sensitivity and specificity of blood tests is poor. Next-generation sequencing (NGS) has greater detection rate for mycobacterium tuberculosis, anaerobes and fungi and greater sensitivity compare with blood tests. However use of NGS is limited because of the short read-length. Oxford nanopore adaptive sequencing (NAS) method is the Third Revolution in Sequencing Technology. For each 1 Gbp of data, NAS sequencing detected 45 times more microbiome sequences than Nanopore standard sequencing and 2.5 times more than Illumina sequencing. The purpose of this study is to compare NAS with NGS and laboratory tests for the diagnostic rate of infection post liver transplantation.

Detailed description

Based on the previous work, the investigators found that: 1. NAS has a higher microbial enrichment efficiency and can detect pathogenic information more quickly compared with nanopores normal sequencing (NNS); 2. NAS can detect more specific pathogen fragments with short-time sequencing; 3. NAS can cover more pathogenic genomes than NNS in a short-time; 4. NAS can detect antibiotic resistance information of pathogenic bacteria in clinical samples.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTNAS, NGS and Laboratory testsUsing three diffrent detection methods and comparing their efficiency

Timeline

Start date
2024-10-01
Primary completion
2026-08-01
Completion
2026-10-30
First posted
2024-08-07
Last updated
2024-08-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06542042. Inclusion in this directory is not an endorsement.